Harvard Bioscience Inc
NASDAQ:HBIO

Watchlist Manager
Harvard Bioscience Inc Logo
Harvard Bioscience Inc
NASDAQ:HBIO
Watchlist
Price: 0.5883 USD 2.3% Market Closed
Market Cap: $26.2m

Operating Margin

-2.2%
Current
Improving
by 0.8%
vs 3-y average of -3%

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-2.2%
=
Operating Income
$-1.9m
/
Revenue
$87.4m

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-2.2%
=
Operating Income
$-1.9m
/
Revenue
$87.4m

Peer Comparison

Country Company Market Cap Operating
Margin
US
Harvard Bioscience Inc
NASDAQ:HBIO
25.6m USD
Loading...
US
PerkinElmer Inc
LSE:0KHE
1.3T USD
Loading...
US
Thermo Fisher Scientific Inc
NYSE:TMO
236.2B USD
Loading...
US
Danaher Corp
NYSE:DHR
166.4B USD
Loading...
KR
Samsung Biologics Co Ltd
KRX:207940
82.9T KRW
Loading...
CH
Lonza Group AG
SIX:LONN
38.5B CHF
Loading...
US
IQVIA Holdings Inc
NYSE:IQV
41.4B USD
Loading...
CN
WuXi AppTec Co Ltd
SSE:603259
274.7B CNY
Loading...
US
Agilent Technologies Inc
NYSE:A
38.7B USD
Loading...
US
Mettler-Toledo International Inc
NYSE:MTD
29.3B USD
Loading...
FR
Sartorius Stedim Biotech SA
PAR:DIM
19.9B EUR
Loading...

Market Distribution

In line with most companies in the United States of America
Percentile
33rd
Based on 14 112 companies
33rd percentile
-2.2%
Low
-4 087 900% — -5.1%
Typical Range
-5.1% — 14.8%
High
14.8% — 1 032 600%
Distribution Statistics
the United States of America
Min -4 087 900%
30th Percentile -5.1%
Median 6%
70th Percentile 14.8%
Max 1 032 600%

Harvard Bioscience Inc
Glance View

Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products and services that enable fundamental research, discovery, and pre-clinical testing for drug development. The company is headquartered in Holliston, Massachusetts and currently employs 475 full-time employees. The company went IPO on 2013-10-21. The firm provides products that support research in six different classes of laboratory use, including molecular, cellular, tissue, organ, organisms or preclinical, and clinical. The firm organizes its product line activities into two product families, Cellular and Molecular Technologies (CMT) and Preclinical. The company primarily sells its products under several brand names, including Harvard Apparatus, DSI, Ponemah, Buxco, Biochrom, BTX, and MCS. The firm's customers include pharmaceutical and biotechnology companies, as well as contract research organizations, academic labs, and government researchers.

HBIO Intrinsic Value
2.8012 USD
Undervaluation 79%
Intrinsic Value
Price
What is Operating Margin?
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
How is Operating Margin calculated?

Operating Margin is calculated by dividing the Operating Income by the Revenue.

Operating Margin
-2.2%
=
Operating Income
$-1.9m
/
Revenue
$87.4m
What is Harvard Bioscience Inc's current Operating Margin?

The current Operating Margin for Harvard Bioscience Inc is -2.2%, which is above its 3-year median of -3%.

How has Operating Margin changed over time?

Over the last 3 years, Harvard Bioscience Inc’s Operating Margin has increased from -4.2% to -2.2%. During this period, it reached a low of -5.7% on Dec 31, 2024 and a high of 2% on Dec 31, 2023.

Back to Top